Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Feb;88(2):113-5.
doi: 10.1002/ajh.23361. Epub 2012 Dec 8.

Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma

Maike Sauer  1 , Annette Plütschow, Ron D Jachimowicz, Dominik Kleefisch, Katrin S Reiners, Sabine Ponader, Andreas Engert, Elke Pogge von Strandmann
Affiliations
Free article
Randomized Controlled Trial

Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma

Maike Sauer et al. Am J Hematol. 2013 Feb.
Free article

Abstract

Hodgkin lymphoma (HL) has become one of the best curable cancers. However, better biomarkers are needed for outcome prediction that would allow protecting patients from over- or under-dosing of treatment. Thymus and activation-regulated chemokine/CCL17 (TARC) is highly and specifically elevated in this disease and has been proposed as possible biomarker in HL patients. In this study, we show that pretreatment TARC levels were associated with established clinical risk factors and predictive for response to treatment in a large cohort of HL patients treated in clinical trials by the German Hodgkin Study Group. Moreover, TARC levels also significantly contributed to a novel multivariate model predicting treatment response. These data clearly suggest an important role for this chemokine as biomarker in HL.

Trial registration: ClinicalTrials.gov NCT00515554.

PubMed Disclaimer

Publication types

Associated data